<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499209</url>
  </required_header>
  <id_info>
    <org_study_id>XG005-01</org_study_id>
    <nct_id>NCT04499209</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of XG005 Capsule</brief_title>
  <official_title>A Phase 1, Single-Center, Randomized, Placebo-Controlled, Ascending Single-Dose Study of the Pharmacokinetics, Safety, and Tolerability of Oral XG005 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xgene Pharmaceutical Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xgene Pharmaceutical Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase 1, single-center, randomized, placebo-controlled, 2-period, ascending&#xD;
      single-dose study assessing the PK, safety, and tolerability of single ascending doses of&#xD;
      XG005 (Period 1) and the naproxen and pregabalin combination (Period 2), in 5 dose groups&#xD;
      each with 10 subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Period 1 was double-blind and randomized 8 subjects (1:1 allocation ratio by gender) to XG005&#xD;
      and 2 subjects (1:1 allocation ratio by gender) to placebo. Subjects were enrolled&#xD;
      sequentially into a total of 5 ascending dose levels pending safety review, and PK review&#xD;
      where possible, of Period 1 of the prior dose level. Sentinel dose participants (1 for XG005&#xD;
      and 1 for placebo) were included as the first dose administered at each dose level in Period&#xD;
      1.&#xD;
&#xD;
      In Period 2, all subjects in the last three XG005 dose groups received approximate molar&#xD;
      equivalents of naproxen and pregabalin corresponding to XG005 doses after a 7-day washout&#xD;
      period. Period 2 was open-label with 10 subjects per group.&#xD;
&#xD;
      PK blood samples in each treatment period were collected at 0 (pre-dosing), 0.5, 1, 1.5, 2,&#xD;
      3, 4, 6, 8, 12, 24, 48, and 72 hrs after drug administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Actual">March 19, 2018</completion_date>
  <primary_completion_date type="Actual">January 18, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Period 1: ascending single-dose of XG005 vs Placebo; Period 2: combination of Naproxen and Pregabalin</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Period 1: Participants and investigators were blinded Period 2: Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Day1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>Day1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 to last measurable time-point (AUC0-t)</measure>
    <time_frame>Day1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 to infinity (AUC0-inf)</measure>
    <time_frame>Day1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Rate Constant (kel)</measure>
    <time_frame>Day1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>Day1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal clearance (CL/F)</measure>
    <time_frame>Day1 to Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vd/F)</measure>
    <time_frame>Day1 to Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence and severity of adverse events (AEs)</measure>
    <time_frame>Day -1 to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>Day -1 to Day 8</time_frame>
    <description>vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>Day -1 to Day 8</time_frame>
    <description>vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory rate</measure>
    <time_frame>Day -1 to Day 8</time_frame>
    <description>vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>temperature</measure>
    <time_frame>Day -1 to Day 8</time_frame>
    <description>vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical examination</measure>
    <time_frame>Day -1 to Day 8</time_frame>
    <description>Cardiovascular, Ears, Nose and Throat, Eyes, Gastrointestinal, Head, Lymph Nodes, Musculoskeletal, Neurological, Respiratory, Skin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrocardiogram (ECG) parameters;</measure>
    <time_frame>Day -1 to Day 8</time_frame>
    <description>ECG-PR, RR, QRS, QT, and QTc intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical laboratory parameters -chemistry</measure>
    <time_frame>Day -1 to Day 8</time_frame>
    <description>BUN, Creatinine, Total bilirubin, Total protein, Alkaline phosphatase, Uric Acid, Estimated creatinine clearance, Creatine Phosphokinase (CPK), AST (SGOT), ALT (SGPT), Glucose, Sodium, Potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical laboratory parameters- hematology</measure>
    <time_frame>Day -1 to Day 8</time_frame>
    <description>Hemoglobin, Hematocrit, Red Blood Cell Count, White Blood Cell Count with differential, Platelet Count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical laboratory parameters urinalysis</measure>
    <time_frame>Day -1 to Day 8</time_frame>
    <description>pH • Specific gravity • Protein&#xD;
Glucose • Ketones • Bilirubin&#xD;
Blood • Nitrite • Urobilinogen&#xD;
Leukocytes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Period 1- XG005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XG005 capsule in 4 dose level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2- Naproxen and Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combination of Naproxen and Pregabalin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 1- Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>XG005 matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XG005</intervention_name>
    <description>XG005 Capsule</description>
    <arm_group_label>Period 1- XG005</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of Naproxen and Pregabalin</intervention_name>
    <description>Naproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica</description>
    <arm_group_label>Period 2- Naproxen and Pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo Capsule</description>
    <arm_group_label>Period 1- Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI range of 18-30 kg/m2&#xD;
&#xD;
          -  Medically healthy subjects&#xD;
&#xD;
          -  Creatinine clearance ≥ 80 mL/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of significant diseases&#xD;
&#xD;
          -  History or presence of alcoholism or drug abuse&#xD;
&#xD;
          -  Consumption of alcohol 48 hours prior each dose&#xD;
&#xD;
          -  Hypersensitivity or idiosyncratic reaction to the study drug&#xD;
&#xD;
          -  Abnormal diet (for whatever reason) during the 30 days prior to the first dosing;&#xD;
&#xD;
          -  Donation (standard donation amount or more) of blood or blood products&#xD;
&#xD;
          -  Plasma donation within 7 days prior to the study;&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to the first dose;&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating;&#xD;
&#xD;
          -  Hemoglobin &lt; 120 g/L&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

